SEC Form SC 13G/A filed by Intuitive Surgical Inc. (Amendment)
$ISRG
Industrial Specialties
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $522.00 → $650.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/2/2024 | $380.00 → $510.00 | Neutral → Buy | Redburn Atlantic |
| 7/10/2024 | $462.00 → $512.00 | Buy | Citigroup |
| 5/30/2024 | $500.00 | Buy | Goldman |
| 11/17/2023 | $318.00 | Buy | HSBC Securities |
| 7/19/2023 | $377.00 | Outperform | Robert W. Baird |
| 4/19/2023 | $240.00 → $270.00 | In-line | Evercore ISI |
| 4/19/2023 | $305.00 → $317.00 | Buy | Citigroup |
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
SANTA CLARA, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (NASDAQ:ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced the appointment of Dr. Craig Barratt to its Board of Directors. Dr. Barratt is a seasoned technology industry veteran with decades of experience as an impactful leader and board member at networking, semiconductor, and medical device companies. "Craig's proven track record of scaling high-growth technology companies and driving breakthrough innovations at industry leaders like Atheros, Google, and Qualcomm makes him an invaluable addition to Astera Labs' Board of Directors," said Jitendra Moh
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
SUNNYVALE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2025. Q1 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the first quarter of 2024.The Company placed 367 da Vinci surgical systems, compared with 313 in the first quarter of 2024. The first quarter 2025 da Vinci surgical system placements included 147 da Vinci 5 systems, compared with 8 in the first quarter of 2024.The Company grew its da Vinci surgical system installed base to 10,189 systems as of Mar
SUNNYVALE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), today announced the publication of two studies showing how the availability of RAS helps enable access to high-quality care, improve patient outcomes, particularly in medical deserts, and contributes to the overall growth of minimally invasive care ultimately benefitting patients. The studies, published in the Journal of the Society of Laparoscopic & Robotic Surgeons and Annals of Surgery Open, are part of broader research underway by Intuitive to evaluate the availability and impact of RAS. As a leader in minimally in
SUNNYVALE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) cleared the company's fully wristed SP SureForm 45 stapler for use with its da Vinci SP surgical system in thoracic, colorectal, and urologic procedures. Like its multiport counterparts, the SP SureForm 45 features SmartFire technology, which continuously monitors tissue compression before and during firing. This real-time optimization helps surgeons enhance staple line integrity and reduce the risk of tissue damage across varying thicknesses. "Being
Morgan Stanley upgraded Intuitive Surgical from Equal-Weight to Overweight and set a new price target of $650.00 from $522.00 previously
Redburn Atlantic upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $510.00 from $380.00 previously
Citigroup reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $512.00 from $462.00 previously
SUNNYVALE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2025. Q1 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the first quarter of 2024.The Company placed 367 da Vinci surgical systems, compared with 313 in the first quarter of 2024. The first quarter 2025 da Vinci surgical system placements included 147 da Vinci 5 systems, compared with 8 in the first quarter of 2024.The Company grew its da Vinci surgical system installed base to 10,189 systems as of Mar
SUNNYVALE, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2024. Q4 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.The Company placed 493 da Vinci surgical systems, compared with 415 in the fourth quarter of 2023. The fourth quarter 2024 da Vinci surgical system placements included 174 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,902 systems as of December 31, 2024, an increase of 15%
SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.Full year 2024 worldwide da Vinci procedures grew approximately 17% compared with 2023. The Company expects worldwide da Vinci procedures to i
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
10-Q - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
DEFA14A - INTUITIVE SURGICAL INC (0001035267) (Filer)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)